First-line medical thoracoscopy for pleural infection: the SPIRIT randomised controlled feasibility trial
Rattachement africain : gb, sa, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Pleural infection remains a significant clinical challenge, requiring hospitalisation, intravenous antibiotics and early chest drain insertion. Medical thoracoscopy (MT), a minimally invasive procedure used electively in the UK for malignant effusions, has demonstrated good outcomes when applied to acute pleural infection in retrospective case series. However, it has not been evaluated as a first-line intervention in the UK in a randomised controlled trial (RCT). OBJECTIVES: The Studying Pleuroscopy in Routine Pleural Infection Treatment (SPIRIT) trial assessed the feasibility of conducting a full-scale RCT comparing MT with chest drain insertion for acute pleural infection within UK National Health Service (NHS) hospitals. METHODS: SPIRIT was an open-label, randomised feasibility trial conducted across seven NHS centres between 2017 and 2019. Adults with suspected pleural infection were prescreened; eligible patients were randomised to either chest drain insertion (control) or MT (performed the same or following day) with 90-day follow-up. The primary outcome was feasibility, assessed through a composite of prescreen, screen and allocation failure rates. Secondary outcomes included inpatient-stay duration, mortality, radiological and microbiological outcomes, second-line interventions, patient-reported outcomes and adverse events. RESULTS: Of 193 patients prescreened, 181 (93.8%) were excluded due to at least one criterion. Key factors included lack of MT deliverability (49.2%), a not truly infected effusion (45.1%) and contraindications to drainage or study involvement (44.0%). Consequently, the primary feasibility endpoint was not met. All 12 eligible patients were randomised with no attrition. MT lasted 15 min longer than drain insertion, but chest drains remained in situ over 3 days longer (p=0.17) with a longer hospital stay (p=0.57). Radiological improvement, microbiological yield and symptom scores were similar. Adverse events occurred in one control and three MT patients. CONCLUSION: A full-scale RCT is not likely to be feasible in an NHS setting on the proposed protocol. Targeted recruitment from centres equipped for emergency MT may enhance feasibility. TRIAL REGISTRATION NUMBER: ISRCTN98460319.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- First-line medical thoracoscopy for pleural infection: the SPIRIT randomised controlled feasibility trial
- Date Crossref
- 01/12/2025
- Éditeur
- BMJ
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Southmead Hospital Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
At Bristol pays non établi dans la noticeOrganisation à but non lucratif
-
University of Bristol Respiratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
St Thomas' Hospital pays non établi dans la noticeÉtablissement de santé
-
King Faisal Specialist Hospital & Research Centre pays non établi dans la noticeÉtablissement de santé
-
The Royal Free Hospital pays non établi dans la noticeÉtablissement de santé
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
Blacktown & Mount Druitt Hospital pays non établi dans la noticeÉtablissement de santé
-
Gloucestershire Hospitals NHS Foundation Trust Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
Manchester Academic Health Science Centre pays non établi dans la noticeÉtablissement de santé
-
Wythenshawe Hospital pays non établi dans la noticeÉtablissement de santé
-
Oxford BioMedica (United Kingdom) pays non établi dans la noticeEntreprise
Respiratory Medicine — Southmead Hospital, At Bristol et Respiratory Medicine — University of Bristol, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.